AstraZeneca received acceptance of its EU marketing applications for Dato-DXd from the EMA. "AstraZeneca Gets EU Marketing Approvals for Cancer Drug," at 0720 GMT, incorrectly said it had received EU marketing approvals. The correct version follows:


By Christian Moess Laursen


AstraZeneca said it is progressing its cancer drug Dato-DXd following acceptance of two European Union marketing applications from the European Medicines Agency.

The pharmaceutical giant said Monday that the EMA has accepted the EU marketing applications for Dato-DXd in the treatment of lung cancer and breast cancer.

Following the validations, the scientific review process by the EMA's Committee for Medicinal Products for Human Use will begin, AstraZeneca said.

"Today's dual validation of our applications in lung and breast cancers brings this potential medicine a meaningful step closer to redefining treatment expectations for patients with two of the most common cancers in Europe," Executive Vice President for oncology research and development, Susan Galbraith, said.

Dato-DXd, or Datopotamab deruxtecan, is a specifically engineered antibody drug conjugate, discovered by Daiichi Sankyo and jointly developed by AstraZeneca and Daiichi Sankyo.


Write to Christian Moess Laursen at christian.moess@wsj.com


(END) Dow Jones Newswires

03-04-24 0415ET